ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy

Oncology (Switzerland)

Volumn 83, Issue 4, 2012, Pages 218-227

  Kim, Ji Won ^a,c   Kim, Jee Hyun ^a   Im, Seock Ah ^a,c   Kim, Yu Jung ^a   Han, Hye Suk ^a   Kim, Jin Soo ^a   Han, Sae Won ^a,c   Jeon, Yoon Kyung ^b,c   Oh, Do Youn ^a,c   Han, Wonshik ^a,c   Kim, Tae You ^a,c   Park, In Ae ^b,c   Noh, Dong Young ^a,c   Bang, Yung Jue ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Department of Pathology ^*  (South Korea)

^c Seoul National University   (South Korea)

Author keywords

ABCB1; FCGR2A; FCGR3A; Polymorphism; Taxane; Trastuzumab

Indexed keywords

CD16 ANTIGEN; DOCETAXEL; FC GAMMA RECEPTOR IIIA; FC RECEPTOR IIA; GENOMIC DNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; GENETIC POLYMORPHISM; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHARMACOGENETICS; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM METASTASIS; P-GLYCOPROTEIN; PACLITAXEL; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, IGG; SURVIVAL RATE; TAXOIDS;

EID: 84865054217     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000341359     Document Type: Article

References (34)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182. (Pubitemid 17231334)
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712. (Pubitemid 19147683)
3. Ross JS, Fletcher JA: The HER-2/neu onco-gene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Oncologist 1998; 3:237-252.
4. Kong SY, Leedo H, Lee ES, Park S, Lee KS, Ro J: Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer. Cancer Res Treat 2006; 38: 35-39.
5. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM: Randomized phase II trial of the efficacy and safety of trastuzu mab combined with doceta xel in patients with human epidermal growth factor receptor 2-pos-itive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-4274. (Pubitemid 46207001)
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672. (Pubitemid 41464705)
7. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684. (Pubitemid 41464706)
8. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58. (Pubitemid 37328807)
9. Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, Jansen RL, van Herpen CM, Soesan M, Beijnen JH, Schellens JH: Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 2006; 12:5786-5793. (Pubitemid 44629610)
10. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C: Mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to pacli-taxel chemotherapy. Clin Cancer Res 2006; 12: 854-859. (Pubitemid 43259868)
11. Chang H, Rha SY, Jeung HC, Im CK, Ahn JB, Kwon WS, Yoo NC, Roh JK, Chung HC: Association of the ABCB1 gene polymorphisms 2677G 1 T/A and 3435C 1 T with clinical outcomes of paclitaxel monotherapy in meta-static breast cancer patients. Ann Oncol 2009; 20:272-277.
12. Chang H, Rha SY, Jeung HC, Im CK, Noh SH, Kim JJ, Chung HC: Association of the ABCB13435C 1 T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol Rep 2010; 23: 271-278.
13. Valabrega G, Montemurro F, Aglietta M: Trastuzumab: mechanism of action, resistance and future perspectives in HER2-over-expressing breast cancer. Ann Oncol 2007; 18: 977-984. (Pubitemid 47050487)
14. Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51. (Pubitemid 47026733)
15. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fer-meaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B: Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006; 94: 259-267. (Pubitemid 43151545)
16. Fanger MW, Shen L, Graziano RF, Guyre PM: Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today 1989; 10: 92-99. (Pubitemid 19087465)
17. Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947. (Pubitemid 46606207)
18. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCRG2A and FCRG3A polymorphisms associated w it h clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25:3712-3718. (Pubitemid 47372612)
19. Bibeau F, Lopez-Crapez E, Di Fiore F, The-zenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frebourg T, Michel P, Sa-bourin JC, Boissiere-Michot F: Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27:1122-1129.
20. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-1796.
21. Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC: Fc gamma RIIIa and Fc gamma RIIIa polymorphisms do not predict response to rituximab in B-cell chronic lym-phocytic leukemia. Blood 2004; 103:1472-1474. (Pubitemid 38168664)
22. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American society of clinical oncology/college of american pa-thologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-145. (Pubitemid 350003059)
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors-European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
24. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-174. (Pubitemid 32225417)
25. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W: Multidrug resistance polypeptide 1 (M DR1, ABCB1) varia nt 3435C 1 T af fects mRNA stability. Pharmacogenet Genomics 2005; 15: 693-704. (Pubitemid 41345321)
26. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Ger-loff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one al-lele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478. (Pubitemid 30183327)
27. Taheri M, Mahjoubi F, Omranipour R: Ef fect of MDR1 poly morph ism on mu ltid r u g resis-tance expression in breast cancer patients. Genet Mol Res 2010; 9: 34-40.
28. Binstadt BA, Geha RS, Bonilla FA: IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobu-lin therapy. J Allergy Clin Immunol 2003; 111: 697-703. (Pubitemid 36470236)
29. Salmon JE, Edberg JC, Brogle NL, Kimberly RP: Allelic polymorphisms of human Fc gamma receptor IIa and Fc gamma receptor IIIb: independent mechanisms for differences in human phagocyte function. J Clin Invest 1992; 89:1274-1281.
30. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M: Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gam-maRIIIa, independently of the Fc gam-maRIIIa-48L/R/H phenotype. Blood 1997; 90:1109-1114. (Pubitemid 27314146)
31. Hurvitz S, Betting D, Stern H, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Robert N, Valero V, Crown J, Driga A, Bee V, Slamon D, Timmerman J: Analysis of Fc{gamma} receptor IIa and IIIa polymorphisms: correlation with outcome in trastuzumab-treated HER2/neu amplified early and metastatic breast cancer patients (abstract). Cancer Res 2009; 69:64.
32. Saijo N: Critical comments for roles of bio-markers in the diagnosis and treatment of cancer. Cancer Treat Rev 2012; 38:63-67.
33. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all her-2 overexpressors and random assignment to trastuzumab or not in her-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26: 1642-1649.
34. Sato N, Sano M, Tabei T, Asaga T, Ando J, Fujii H, Yamamoto N, Kurosumi M, Inoue K, Kimura M: Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study. Breast Cancer 2006; 13: 166-171.